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In this issue of the Journal, Ioannidis et al. (1) report the
results of a meta-analysis of seven studies on creatine
kinase-MB isoenzyme (CK-MB) elevation after percutane-
ous coronary intervention (PCI) and its relationship to
subsequent mortality. As in earlier reports, the authors
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confirmed a significant relationship between peri-procedural
CK-MB elevation 3  the upper limit of normal (ULN)
and subsequent mortality. Additionally, they also found that
patients with CK-MB elevation between 1 to 3  ULN,
which usually occurs with no associated clinical event, were
at increased risk for late mortality. The latter finding
extends the previous debate regarding the clinical signifi-
cance of asymptomatic biomarker release (2,3).
Our comments focus on four key elements of this study:
1) its theoretical background; 2) its methodologic strengths
and limitations; 3) the biologic plausibility of its findings;
and 4) its clinical implications for prevention and therapy.
BACKGROUND
In 1991, Klein et al. (4) first reported that although CK
elevation occurred in 15% of patients after otherwise-
successful balloon angioplasty, it appeared to have no
significant impact on in-hospital outcomes. Over the last
decade, numerous investigators have studied this phenom-
enon in PCI registries (5–9) and clinical trial cohorts
(10,11), extending the analyses to different patient popula-
tions and interventional devices, more cardiac-specific bio-
marker assays (CK-MB and cardiac troponins), and longer
follow-up periods. From this body of work, a number of
important generalizations can be made:
● When routinely measured, biomarker release after PCI is
common, occurring in 5% to 30% of cases: most of these
are minor releases.
● Biomarker release is associated with several patient (age,
acute coronary syndrome), angiographic (multivessel dis-
ease, saphenous vein graft intervention, intracoronary
thrombus), and procedural (non-balloon device use) fac-
tors.
● Large elevations in biomarker release (e.g., CK-MB
release 5 to 8  ULN) are independently associated
with late mortality.
● Small elevations in biomarker release have been incon-
sistently associated with late mortality.
Understandably, expert panels have varied in their interpre-
tation of the clinical importance of these findings. Some
have recommended the routine measurement of CK-MB
(or other biomarkers) after PCI (12,13), whereas others
suggest measurement only if driven by evidence of: 1)
angiographic complications during PCI (i.e., side-branch
occlusion), or 2) clinical ischemia (angina, arrhythmia,
hypotension) (14,15). Many (12,14) have agreed that the
threshold of 3  ULN for CK-MB elevation, despite
being somewhat arbitrary, should be used to define a
peri-procedural myocardial infarction. A notable exception
to this standard is the consensus statement from the Joint
European Society of Cardiology/American College of Car-
diology Committee for the Redefinition of Myocardial
Infarction (13). This committee recommended that any rise
above normal for CK-MB or cardiac troponins in the
setting of PCI be considered a myocardial infarction. The
meta-analysis by Ioannidis and colleagues (1) supports this
recommendation. Yet, the new American Heart Association
Diagnostic and Interventional Catheterization Committee
recommendation (15) raising the CK-MB diagnostic
threshold to 5 to 8  ULN may be more clinically relevant
in the context of more recent data.
METHODOLOGICAL ISSUES
Meta-analyses are generally reserved for pooling the results
of randomized clinical trials (RCTs), where bias between
the groups of patients being observed is minimized by study
design. Combining the results of observational studies,
although statistically feasible, is less common and has several
theoretical disadvantages: 1) variable definitions of risk
markers and outcomes; 2) widespread differences in the
“quality” of the studies; and 3) a limited ability to adjust for
potential sources of confounding between risk markers and
outcomes.
The study by Ioannidis et al. (1) combined the results of
seven published studies that included a total of 23,230
patients. The studies were reported between 1994 and 2002,
included asymptomatic patients (with four studies specifi-
cally excluding patients with major complications after
PCI), involved the use of a wide variety of devices, and used
variable assays and protocols for the measurement of
CK-MB after PCI. Overall, the authors found the incidence
of peri-procedural CK-MB elevation to be 31% with the
risk of late mortality rising proportionately with increasing
biomarker elevations. Importantly, this risk was present
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Cardiovascular Diseases, Department of Internal Medicine,
University of Michigan, Ann Arbor, Michigan.
Journal of the American College of Cardiology Vol. 42, No. 8, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)01037-4
even when the degree of CK-MB elevation was only 1 to 3
 ULN, suggesting a “dose-response” relationship between
biomarker release and subsequent mortality. By pooling
results from the seven studies, the authors were able to
increase the statistical power needed to detect this smaller,
yet potentially clinically important outcome.
How strongly can we believe the conclusion that minor
CK-MB elevations are associated with late mortality? One
of the major limitations of this study is the fact that
summary risk estimates reported were unadjusted. Because
the influence of confounding is most crucial when the
overall association between a risk marker and outcome is
small, this is particularly important in the case of minor
CK-MB elevations. Without proper adjustment for patient,
angiographic, and procedural factors known to be associated
with both CK-MB elevation and worse long-term survival,
it is impossible to know whether biomarker release after
PCI is simply a marker of disease severity or directly
responsible for subsequent mortality. Determining indepen-
dent association is a critical first step in understanding
whether any epidemiological relationship is causal and this
usually requires a prospective RCT. Unfortunately, none
have been performed on this topic.
BIOLOGIC PLAUSABILITY
Another crucial step in establishing causality depends on
understanding how well a relationship correlates with a
pre-existing body of knowledge. Not until Ricciardi et al.
(16) demonstrated that mild CK-MB elevations after PCI
were related to discrete microinfarctions detected by
contrast-enhanced magnetic resonance imaging was it clear
that biomarker release was directly related to myocardial
necrosis and not just due to profound ischemia from
transient coronary artery occlusion during PCI. Several
potential mechanisms have been postulated for causing
PCI-related myocardial necrosis, including: 1) distal embo-
lization, 2) the no-reflow phenomenon, 3) transient vessel
closure from dissection or spasm, and 4) side-branch occlu-
sion. Importantly, it appears that myocardial necrosis often
occurs when PCI is otherwise “successful” with no clinically
detectable complications.
However, the more difficult relationship to understand,
from a standpoint of biologic plausibility, is how minor
CK-MB elevations after PCI can lead to increased mortality
several years after the procedure as suggested by the study by
Ioannidis et al. (1) and earlier reports (5,6). Previous
theories suggest that CK-MB elevations might lead to a
heightened adrenergic or inflammatory state post-PCI or
induce long-term arrhythmic instability from an infarct
substrate even in the absence of substantial myocardial
damage (12). In addition, it has been proposed that minor
elevations may represent microembolization and compro-
mise of potential distal collateral channels (2).
More recently, others (17,18) have suggested that plaque
characteristics, including total atherosclerotic burden or
plaque instability, are related to peri-procedural CK-MB
elevations; thus, biomarker release after PCI actually “se-
lects” for those patients with complex plaques who are at the
highest risk for recurrent events. This suggestion appears to
be more consistent with recent data from Ellis et al. (8) that
identified an early four-month high-risk period of events for
patients with any PCI-related CK-MB release in addition
to a late mortality risk beyond 12 months. Interestingly,
they also suggested that high inflammatory states and
high-risk clinical features (such as incomplete revasculariza-
tion and congestive heart failure) amplified risk in patients
with peri-procedural CK-MB release. This appears to
indicate that biomarker elevations, especially mild eleva-
tions, may be risk markers for disease or lesion severity and
not causal mediators of late mortality.
CLINICAL IMPLICATIONS
From a clinical perspective, there are two practical questions
for interventional cardiologists: 1) how can we minimize
PCI-related biomarker elevations, and 2) should those with
biomarker elevations be treated differently from those with
normal biomarker levels after PCI?
Despite whether one believes that minor biomarker
elevations are clinically important or not, minimizing such
elevations after PCI is a reasonable goal because they
represent myocardial necrosis. It is well established that
glycoprotein IIb/IIIa inhibitors reduce the incidence of
biomarker elevations after PCI, although of interest to this
debate, there is no impact on six-month mortality (19).
Other therapies believed to reduce the extent of CK-MB
elevations include pre-procedural drug therapies, such as
beta-blockers (20) and statins (21), and intraprocedural
therapies, such as ischemic preconditioning (22) and intra-
coronary adenosine (23). However, data on these therapies
have been sparse overall and, in the case of beta-blockers
(24), conflicting. Recently, distal protection devices have
been shown to substantially lower the incidence of biomar-
ker release after PCI in saphenous vein graft interventions
(25). When possible, the avoidance of atherectomy devices,
which increase the risk of biomarker release, should also be
considered.
If PCI-related biomarker elevation does occur, should
these patients be treated as if they had had a spontaneous
acute coronary syndrome? Extended monitoring of patients
with minor elevations is unlikely to be beneficial. Two
studies (7,8) showed no significant differences in in-hospital
events between those patients with CK-MB elevation 1 to 5
 ULN and patients with no CK-MB elevation.
No RCTs have been performed to evaluate specific
therapies in patients with biomarker release after PCI.
There is evidence that these patients have a higher inflam-
matory state and potentially might benefit from more
aggressive statin use (26). Also, these individuals may
represent a high-risk subgroup of patients that would obtain
the greatest benefit from prolonged dual anti-platelet ther-
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apy with aspirin and clopidogrel. Beta-blockers and
angiotensin-converting enzyme inhibitors may also be ap-
propriate to reduce arrhythmic instability and improve
remodeling after myocardial necrosis.
We strongly support the recommendation that CK-MB
or troponin levels should be measured before and after PCI
(12,13). Patients with periprocedural myocardial infarction
have a worse prognosis than if biomarkers had remained
normal and this knowledge may be clinically useful. In
particular, patients with biomarker elevation 5 to 8 
ULN or new Q waves have had a clinically significant
complication. However, it should be recognized that patient
outcome and prognosis may be significantly improved by
the revascularization procedure despite a small peri-
procedural myocardial infarction. The benefit of revascular-
izing a stenotic artery causing progressive or unstable angina
or moderate or severe myocardial ischemia should far
outweigh the negative impact of a small, especially asymp-
tomatic, biomarker elevation (13). This fact has been lost in
the debate about small peri-procedural myocardial infarc-
tion because there has not been a control group without
revascularization against which to compare long-term out-
come. Age, clinical presentation, left ventricular function,
atherosclerotic burden, completeness of revascularization,
objective demonstration of myocardial ischemia, and risk
factor control success remain the strongest proven prognos-
tic indicators after successful PCI.
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